Page 14 - Anjali Singh

HDFC Bank to pursue legal remedies against Mehta family of Lilavati Trust

The bank rejected the "malicious and baseless allegations" levelled against HDFC Bank's MD and CEO Sashidhar Jagdishan

Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda

The partnership marks a strategic boost to Dr Reddy's oncology portfolio and expands Alvotech's biosimilar pipeline as Keytruda patents near expiry

Classic Legends targets FY26 profitability with new launches, expansion

Classic Legends is betting big on product innovation, network expansion, and exports to achieve profit before tax (PBT)-level profitability by FY26, said a senior company executive

Zydus enters biologics CDMO market with $125 million acquisitions

Zydus Lifesciences will acquire two US biologics manufacturing facilities from Agenus for up to $125 million, gaining immediate manufacturing capabilities and expanding its global presence

Two-wheeler majors bounce back with strong double-digit growth in May

Analysts estimate a 4 to 7 per cent rise in FY26, driven by product innovation, supportive policy frameworks, and increasing mobility needs in emerging markets

Glenmark's cancer drug shows strong results in early trial for Myeloma

In the dose-escalation stage of the trial, 35 patients were treated, most of whom had received a median of six prior therapies

Rare earth supply pinch puts India's EV makers on a six-week clock

China controls 92 per cent of global REM magnet production, with other players like Japan (7 per cent) and Vietnam (1 per cent) contributing marginally

Bajaj Auto Q4 results: Net profit falls 10.4% to ₹1,802 cr; revenue up 8%

The decline in the net profit was attributed to subdued performance in the domestic motorcycle market

Schaeffler to invest €500 million in India, opens fifth plant in Tamil Nadu

German firm Schaeffler will invest €500 million in India over five years to grow EV, rail, and renewable businesses and deepen localisation amid global shifts

Aurobindo Pharma Q4 net dips 0.5%, revenue up 10.5% to Rs 8,382 cr

US and Europe markets drive growth as company posts flat profit for Q4 FY25; files 9 ANDAs and launches 5 new products during the quarter

Lupin signs licensing deal with SteinCares for ranibizumab in LatAm

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina

Indian tyre companies draw up road map to steer through tariff jitters

Despite low US exposure, Indian tyre makers are crafting mitigation strategies to address looming tariff threats and persistent margin pressures due to high input costs

Private hospitals step up Covid readiness amid mild case uptick in India

Despite a mild rise in cases and no fresh central advisory, private hospitals across India are enhancing Covid protocols and issuing cautionary measures to safeguard high-risk groups

Private hospitals reinforce Covid-19 readiness amid mild case uptick

Hospitals across India reinstate early-pandemic protocols and bolster isolation facilities as active COVID cases rise, though most remain mild and manageable

Sun Pharma results: Profit down 19% at Rs 2,149.8 cr, revenue up 8%

Sun Pharma attributed the lower growth in the quarter partly to softer sales in January and February in the US, which is a typical trend

Tata Motors bets on Altroz to 2x market share in premium hatchbacks

The 25,000-30,000 units a month premium hatchback segment accounts for nearly 6-7 per cent of passenger vehicle (PV) sales, and is dominated by models like Baleno of Maruti Suzuki

Auto parts sector to grow 7-9% in FY26, driven by 2W, PV demand: Crisil

A moderate recovery in commercial vehicles and tractor sales, which contribute around 17 per cent to overall revenue, is also expected to support growth

Zydus reports 17.6% rise in net profit adjusting for one-off charge

Q4 revenue up 17%

JK Tyre Q4FY25 profit down 42.6% to Rs 97 crore, revenue up 1.63%

JK Tyre's net profit fell 42.6% in Q4FY25 due to raw material inflation; revenue rose modestly, with premium product lines showing strong customer traction

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe